Thomas C. Hamilton
Impact in
- Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.2%
- Drug Transport and Resistance Mechanisms
- Metal complexes synthesis and properties
Papers in
-
- Receptor Mechanisms and Signaling 10
- Genomics, phytochemicals, and oxidative stress 9
- RNA Research and Splicing 8
-
- Ovarian cancer diagnosis and treatment 44
- Co-authors
- Robert F. Ozols (49 shared papers)Andrew K. Godwin (30 shared papers)Robert C. Young (15 shared papers)Steven W. Johnson (19 shared papers)Russell J. Schilder (4 shared papers)A.H. Weston (3 shared papers)Karen R. Grotzinger (8 shared papers)Lainie P. Martin (1 shared paper)
- Journals
- Gynecologic Oncology (12 papers)British Journal of Pharmacology (11 papers)Biochemical Pharmacology (10 papers)Cancer (8 papers)European Journal of Pharmacology (7 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Thomas C. Hamilton
187 papers receiving 13.9k citations
Thomas C. Hamilton's Hit Papers
Peers
Comparison fields: 5 of 157
- Reproductive Medicine 1.9k
- Oncology 4.2k
- Biochemistry 978
- Molecular Biology 7.6k
- Cancer Research 1.5k
Countries citing papers authored by Thomas C. Hamilton
This map shows the geographic impact of Thomas C. Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Hamilton more than expected).
Fields of papers citing papers by Thomas C. Hamilton
This network shows the impact of papers produced by Thomas C. Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Hamilton. The network helps show where Thomas C. Hamilton may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas C. Hamilton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 188 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Hit paper breakdown → | 1992 | 817 |
| 2 | Platinum Resistance: The Role of DNA Repair Pathways Hit paper breakdown → | 2008 | 611 |
| 3 | AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Hit paper breakdown → | 1992 | 582 |
| 4 | Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion Hit paper breakdown → | 1985 | 493 |
| 5 | Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Hit paper breakdown → | 1983 | 471 |
| 6 | Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Hit paper breakdown → | 1987 | 440 |
| 7 | 1986 | 409 | |
| 8 | 1987 | 364 | |
| 9 | 1984 | 350 | |
| 10 | Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. | 1985 | 303 |
| 11 | Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. | 2003 | 266 |
| 12 | 2004 | 250 | |
| 13 | The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. | 1998 | 247 |
| 14 | Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. | 2003 | 242 |
| 15 | 2000 | 230 | |
| 16 | Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. | 1984 | 211 |
| 17 | 1996 | 208 | |
| 18 | 1989 | 200 | |
| 19 | The biology of ovarian cancer. | 1998 | 197 |
| 20 | 1987 | 179 |
About Thomas C. Hamilton
Thomas C. Hamilton is a scholar working on Molecular Biology, Reproductive Medicine, Oncology, Biochemistry and Genetics, having authored 188 papers that have together received 14.4k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (44 papers), Sulfur Compounds in Biology (11 papers), Receptor Mechanisms and Signaling (10 papers), Drug Transport and Resistance Mechanisms (10 papers), Genomics, phytochemicals, and oxidative stress (9 papers), Reproductive Biology and Fertility (9 papers), RNA Research and Splicing (8 papers) and Chemotherapy-induced organ toxicity mitigation (8 papers). The work is most often cited by research in Reproductive Medicine (1.9k citations), Oncology (4.2k citations), Biochemistry (978 citations), Molecular Biology (7.6k citations) and Cancer Research (1.5k citations). Thomas C. Hamilton has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robert F. Ozols, Andrew K. Godwin, Robert C. Young, Steven W. Johnson, Russell J. Schilder, A.H. Weston, Karen R. Grotzinger, Lainie P. Martin, Karen G. Louie and Brent C. Behrens. Their work appears in journals such as Gynecologic Oncology, British Journal of Pharmacology, Biochemical Pharmacology, Cancer and European Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.